28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Among 87,229 matched patients per cohort, GLP-1 RA use was associated with a significantly lower risk of overall dementia (adjusted HR (AHR) 0.90; 95% CI 0.85 to 0.95), Alzheimer's disease (AD) (AHR 0.88; 95% CI 0.83 to 0.94), and non-vascular dementias (non-VaDs) (AHR 0.75; 95% CI 0.70 to 0.81) compared with metformin. 5 key findings →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In men, increasing depressive symptoms were associated with significantly steeper rates of cognitive decline, as measured by global cognitive and functional outcomes, and with an increased risk of dementia compared to consistently low depressive symptoms. 5 key findings →
Design: longitudinal study Participants: 811 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In 893 participants with average age 93 years (range 90-102), 43 % had SMC. 5 key findings →
Design: cross-sectional Participants: 893 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over 13.45 years, 992 all-cause dementia cases were recorded. 5 key findings →
Design: cohort study Participants: 118,963 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 490 783 participants, 21 468 (47.6% women) experienced an incident sepsis hospitalization. 5 key findings →
Design: cohort study Participants: 783 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In total, 156 individuals were assessed for eligibility, and 79 (51%) were recruited (mean age 61.6 ± 6.9 (range 60-75) years; 68% male). 5 key findings →
Participants: 156 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Palliative care was associated with a higher risk of hospitalization in the first 90 days (e.g., hazard ratio (HR) 1.43 at 30 days; 95% confidence interval (CI) 1.25-1.64), which was driven predominantly by hospitalization with palliative intent, but was no longer significantly different beyond 180 days, compared to not receiving palliative care. [Correction added on 31 January 2026, after first online publication: The preceding sentence has been revised in this version.] 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Diabetes was not associated with brain atrophy cross-sectionally or longitudinally. 5 key findings →
Design: cross-sectional Participants: 112 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our aim is to examine the interplay between cerebral small vessel disease (CSVD) pathology, Alzheimer’s disease (AD) related amyloid-β (Aβ) clearance, and cognition in general population. 2 key findings →
Design: cross-sectional Participants: 1,026 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Out of 462,327 eligible participants, those with constipation were associated with higher incidence of three outcome diseases (1415/20,263 [7.0%]) than those without (18,848/442,064 [4.3%]), with adjusted hazard ratio (HR) being 1.35 [1.27-1.42]. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Hypertension, acute myocardial infarction, atrial fibrillation, diabetes, heart failure, ischemic heart disease, stroke, and arthritis additively accounted for 71.8% (95% confidence interval [CI]: 62.9%-79.1%) of ADRD incident cases based on LE-AAF. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Bile acids (BAs) may contribute to dementia by regulating neuroinflammation and influencing gut-brain axis signaling, especially in Alzheimer's disease (AD). 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Vascular cognitive impairment risk factors include stroke, hypertension, diabetes and atherosclerosis. 1 key finding →
Design: meta-analysis Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The incidence rate for AD was significantly higher among African-American and Caribbean Hispanic elderly individuals compared white individuals.
Full summary, score breakdown and related studies → Original source Free full text
This study provides a potential standardized definition for frailty in community-dwelling older adults and offers concurrent and predictive validity for the definition.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In a general population sample, we determined incidence of dementia and of probable AD and will use these incident cases for study of precursors and natural history in this elderly cohort, which has been under close surveillance for over 40 years.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Olive oil (OO) is the most representative food of the traditional Mediterranean Diet (MedDiet). 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The sample included 55.6% patients with MCI and 56 people with SCD. 5 key findings →
Participants: 55 Evidence: low
Full summary, score breakdown and related studies → Original source
In women at higher risk of cognitive decline due to vascular disease or risk factors, adherence to a Mediterranean-style diet was not associated with subsequent 5-year cognitive change. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The Mediterranean diet is currently considered a functional diet with an increasing amount of scientific evidence that supports its beneficial effects in human health. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results confirm that vitamin D deficiency is associated with a substantially increased risk of all-cause dementia and Alzheimer disease. 5 key findings →
Participants: 171 Evidence: low
Full summary, score breakdown and related studies → Original source
We used the medical records linkage system for the population of Rochester, Minnesota, to identify persons in the community who had their first cerebral infarct without previous dementia. 2 key findings →
Participants: 971 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Central auditory dysfunction is a precursor to AD. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Increased SBP and low milk intake in midlife were associated with VaD detected 25 to 30 years later. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We found that 451 (92.8%) of the patients were testable, 239 (49.2%) of the patients were women, and the mean age was 71.2 years. 5 key findings →
Participants: 486 Evidence: moderate
Full summary, score breakdown and related studies → Original source
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →